Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Phase 1 Trial to Evaluate Single and Multiple Ascending Doses of AM 125 (Intranasal Betahistine) in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Placebo Controlled, Phase 1 Trial to Evaluate Single and Multiple Ascending Doses of AM 125 (Intranasal Betahistine) in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betahistine (Primary) ; Betahistine
  • Indications Vertigo
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 07 Mar 2019 Status changed from active, no longer recruiting to completed, according to an Auris Medical media release.
    • 17 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to an Auris Medical media release.
    • 17 Oct 2018 According to an Auris Medical media release, the company will host a conference call and web-cast to review the top-line results from this trial today (October 17, 2018). A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top